Immune checkpoint inhibitors (ICI) have revolutionized therapy for advanced cancer, however many patients still do not respond to treatment. However, […]

The present invention relates to use of soluble CD27 as a biomarker to predict the reponse to an immune checkpoint inhibitor treatment. Inventors have […]

The present invention relates to a method and composition for treating melanoma, aggressive/invasive melanoma, metastatic melanoma or melanoma […]

The present invention relates to a method for assisting with lymphoma prognosis. The prognosis of therapeutic response of patients with lymphoma is […]

Inventors report heterozygous mutations in mitochondrial single-stranded DNA-binding protein SSBP1 in multiple unrelated families with non-syndromic […]

Lung cancers consist of two major histological types, non-small-cell lung carcinoma (NSCLC) and small-cell lung carcinoma. NSCLC consists of squamous […]

Peripheral T-cell lymphomas (PTCLs) are heterogeneous and uncommon non-Hodgkin’s tumor diseases characterized by an aggressive clinical course and a […]

Lung cancer is the most common cause of cancer related death in the world. Approximately 80% to 90% of cases involve Non–Small-Cell Lung Cancer […]

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract, mostly characterized by activating […]

Kidney cancer also called renal cancer, or renal cell carcinoma (RCC) refers to cancer that has arisen from the kidney, and is by far the most common […]